Gsk (GLAXF) Other Operating Expenses (2009 - 2026)

Gsk's Other Operating Expenses history runs 18 years deep, the most recent figure standing at $209.0 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 1608.3% year-over-year to $209.0 million; the TTM figure through Mar 2026 stood at $245.8 million (up 108.73% YoY), while the FY2025 annual figure was $21.1 million, up 101.08% from the prior year.
• Other Operating Expenses was $209.0 million for Q1 2026 at Gsk, up from -$155.6 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $890.3 million in Q4 2022 to a low of -$2.0 billion in Q4 2024.
• Historically, Other Operating Expenses has averaged -$231.5 million across 5 years, with a median of -$155.6 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Other Operating Expenses plunged 520.01% in 2022, then jumped 1608.3% in 2026.
• A 5-year view of Other Operating Expenses shows it stood at $890.3 million in 2022, then tumbled by 179.61% to -$708.7 million in 2023, then sank by 177.09% to -$2.0 billion in 2024, then surged by 92.07% to -$155.6 million in 2025, then soared by 234.27% to $209.0 million in 2026.
• The last three Other Operating Expenses figures came in at $209.0 million (Q1 2026), -$155.6 million (Q4 2025), and $32.4 million (Q3 2025), per Business Quant data.